Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer

키워드

참고문헌 (31)

1. Rosell R, "Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation- positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)[DOI]
2. Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)[DOI]
3. Hyman DM, "Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations", N Engl J Med, 373, pp.726~736 (2015)[DOI]
4. Shaw AT, "Crizotinib in ROS1-rearranged non-small-cell lung cancer", N Engl J Med, 371, pp.1963~1971 (2014)[DOI]
5. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)[DOI]
6. Brahmer J, "Nivolumab versus docetaxel in advanced squamouscell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)[DOI]
7. Kim DW, "Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial", Lancet Oncol, 17, pp.452~463 (2016)[DOI]
8. Ou SH, "Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study", J Clin Oncol, 34, pp.661~668 (2016)[DOI]
9. Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer", J Clin Oncol, 26, pp.3543~3551 (2008)[DOI]
10. Paz-Ares L, "Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a doubleblind, phase 3, randomised controlled trial", Lancet Oncol, 13, pp.247~255 (2012)[DOI]
11. Park S, "Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements", Clin Lung Cancer, 16, pp.e83~e89 (2015)[DOI]
12. Camidge DR, "Anaplastic lymphoma kinase gene rearrangements in nonsmall cell lung cancer are associated with prolonged progressionfree survival on pemetrexed", J Thorac Oncol, 6, pp.774~780 (2011)[DOI]
13. Lee JO, "Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer", J Thorac Oncol, 6, pp.1474~1480 (2011)[DOI]
14. Shaw AT, "Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer", Ann Oncol, 24, pp.59~66 (2013)[DOI]
15. Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)[DOI]
16. Schwartz LH, "Evaluation of lymph nodes with RECIST 1.1", Eur J Cancer, 45, pp.261~267 (2009)[DOI]
17. Sun JM, "Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized phase II trial", J Clin Oncol, 33, pp.2450~2456 (2015)[DOI]
18. Xu CW, "Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues", Exp Ther Med, 9, pp.2151~2154 (2015)[DOI]
19. Takezawa K, "Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer", Br J Cancer, 104, pp.1594~1601 (2011)[DOI]
20. Berge EM, "Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive nonsmall-cell lung cancer", Clin Lung Cancer, 14, pp.636~643 (2013)[DOI]
21. Rangachari D, "Brain metastases in patients with EGFRmutated or ALK-rearranged non-small-cell lung cancers", Lung Cancer, 88, pp.108~111 (2015)[DOI]
22. Costa DB, "Clinical experience with crizotinib in patients with advanced ALKrearranged non-small-cell lung cancer and brain metastases", J Clin Oncol, 33, pp.1881~1888 (2015)[DOI]
23. Costa DB, "CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib", J Clin Oncol, 29, pp.e443~e445 (2011)[DOI]
24. Gettinger SN, "Activity and safety of brigatinib in ALK-rearranged nonsmall-cell lung cancer and other malignancies: a single-arm, openlabel, phase 1", 2 trial, 2016, pp.17, 1683~1696
25. Gandhi L, "High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged nonsmall-cell lung cancer", J Thorac Oncol, 8, pp.e3~e5 (2013)[DOI]
26. Moro-Sibilot D, "Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study", Lung Cancer, 90, pp.427~432 (2015)[DOI]
27. Zhu W, "Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study", J Chemother, 27, pp.221~226 (2015)[DOI]
28. Tanaka T, "The association between the percentage of anaplastic lymphoma kinase(ALK)-positive cells and efficacy of ALK inhibitor (P3.02a-005)", J Thorac Oncol, 12, pp.S1162~ (2017)
29. Lei YY, "Anaplastic lymphoma kinase variants and the percentage of ALKpositive tumor cells and the efficacy of crizotinib in advanced NSCLC", Clin Lung Cancer, 17, pp.223~231 (2016)[DOI]
30. Lee HJ, "HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer", Am J Clin Pathol, 142, pp.755~766 (2014)[DOI]
31. Zito Marino F, "Intratumor heterogeneity of ALK-rearrangements and homogeneity of EGFR-mutations in mixed lung adenocarcinoma", PLoS One, 10, pp.e0139264~ (2015)[DOI]

관련 논문AI추천